Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management.
Fundam Clin Pharmacol
; 2024 Aug 05.
Article
en En
| MEDLINE
| ID: mdl-39102849
ABSTRACT
BACKGROUND:
Being amongst the leading factors of death and distress, chronic kidney disease (CKD) has affected around 850 million people globally. The Wnt/ß-catenin axis is vital for maintaining kidney homeostasis, from nephron generation to overall management. The ß-catenin growth factor is typically not expressed in the adult kidney; however, its expression is found to increase under stress and injury conditions. It is categorised as canonical and non-canonical based on ß-catenin availability, which mounts promising targets for ameliorating CKD. Hence, modulation of the Wnt/ß-catenin signalling for CKD management is of utmost relevance.OBJECTIVES:
The primary aim of this review is to highlight the significance of targeting Wnt/ß-catenin signalling for CKD management.METHODS:
The literature review regarding the role of Wnt/ß-catenin signalling and therapies modulating it in CKD was conducted using PubMed, Scopus, Science Direct and Google Scholar.RESULTS:
The current review summarises the pharmacological therapies modulating the Wnt/ß-catenin axis in CKD, building upon promising preclinical studies to establish a foundation for clinical studies in the future.CONCLUSION:
Wnt/ß-catenin signalling is the evolution's most conserved pathway, which plays a pivotal role in CKD progression. Therapies modulating Wnt/ß-catenin signalling have emerged as effective means for alleviating CKD.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Fundam Clin Pharmacol
Asunto de la revista:
FARMACOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
India
Pais de publicación:
Reino Unido